TIGIT inhibits NK cell-mediated tumor killing, induces immunosuppressive DCs, suppresses CD8 T cell priming and differentiation, and prevents CD8 T cell-mediated killing (Buisson and Triebel, 2005; Li et al., 2014; Fuhrman et al., 2015; Kurtulus et al., 2015; Liu et al., 2015; Kourepini et al., 2016). Here, CD8A is linked to neoplasm.